Abstract
Aortic valve stenosis is the most common adult valve disease in
industrialized countries. The ageing population and the increase in
comorbidities urge the development of safer alternatives to the current
surgical treatment. Sutureless bioprosthesis have shown promising
results, especially in complex procedures and in patients requiring
concomitant surgeries.
Objectives: Assess the clinical and hemodynamic performance,
safety, and durability of the Perceval ® prosthetic
valve.
Methods: This single center retrospective longitudinal cohort
study collected data of all adult patients with aortic valve disease who
underwent aortic valve replacement with a Perceval ®prosthetic valve between February 2015 and October 2020. Of the 196
patients included (mean age 77.20±5.08 years; 45.4% female; mean
EuroSCORE II 2.91±2.20%), the majority had aortic stenosis.
Results: Overall mean cross-clamp and cardiopulmonary bypass
times were 33.31±14.09 and 45.55±19.04 minutes, respectively. Mean ICU
and hospital stay were 3.32±3.24 and 7.70±5.82 days, respectively.
Procedural success was 98,99%, as two explants occurred. 4 valves were
reimplanted due to intra-operative misplacement. Mean transvalvular
gradients were 7.82±3.62 mmHg. Pacemaker implantation occurred in 12.8%
of patients, new-onset atrial fibrillation in 21.9% and renal
replacement support was necessary in 3.1%. Early mortality was 2.0%.
We report no structural valve deterioration, strokes or endocarditis and
one successfully treated valve thrombosis.
Conclusions: Our study confirms the excellent clinical and
hemodynamic performance and safety of a truly sutureless aortic valve,
up to 5-year follow-up. These results were consistent in isolated and
concomitant interventions, solidifying this device as a viable option
for treatment of isolated aortic valve disease.